What is the half-life of venlafaxine (Effexor) in a typical adult patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Venlafaxine

Venlafaxine has an elimination half-life of 5 ± 2 hours, while its active metabolite O-desmethylvenlafaxine (ODV) has a half-life of 11 ± 2 hours at steady state. 1

Pharmacokinetic Details

Parent Compound (Venlafaxine)

  • The elimination half-life ranges from 3-4 hours in most studies, with FDA labeling specifying 5 ± 2 hours at steady state 1, 2, 3
  • Steady-state plasma concentrations are achieved within 3 days of multiple-dose therapy 1
  • Mean steady-state plasma clearance is 1.3 ± 0.6 L/h/kg 1

Active Metabolite (O-desmethylvenlafaxine/ODV)

  • The half-life is approximately 10-11 hours, with FDA labeling specifying 11 ± 2 hours at steady state 1, 4, 5
  • ODV is the only major active metabolite and accounts for much of venlafaxine's therapeutic effect 1
  • Mean steady-state plasma clearance of ODV is 0.4 ± 0.2 L/h/kg 1

Clinical Implications of Short Half-Life

Dosing Frequency

  • The short half-life of venlafaxine necessitates twice-daily or three-times-daily dosing with immediate-release formulations to maintain therapeutic levels 1
  • Extended-release formulations were developed specifically to address the short half-life and allow once-daily dosing 1

Discontinuation Syndrome Risk

  • The short half-life increases risk of withdrawal symptoms if doses are missed or the medication is abruptly stopped 6
  • Tapering over 10-14 days is recommended when discontinuing to minimize withdrawal syndrome 6

Special Populations with Altered Half-Life

Renal Impairment

  • In patients with renal impairment (GFR 10-70 mL/min), venlafaxine half-life is prolonged by approximately 50% 1, 7
  • In dialysis patients, venlafaxine half-life increases by approximately 180% and ODV half-life by 142% 1, 7
  • Dosage adjustment is mandatory in patients with creatinine clearance below 30 mL/min 1, 7

Hepatic Impairment

  • In patients with hepatic cirrhosis, venlafaxine half-life is prolonged by approximately 30% 1
  • ODV half-life is prolonged by approximately 60% in cirrhotic patients 1
  • In Child-Pugh B patients, oral elimination half-life is approximately twice as long as normal subjects 1

Age Considerations

  • In elderly patients, the half-life extends to 11-13 hours for venlafaxine (compared to 5-9 hours in younger adults aged 20-45 years) 8
  • However, dose-normalized trough plasma levels show no significant age-related differences when adjusted for weight 1

References

Research

Venlafaxine:a novel antidepressant compound.

Expert opinion on investigational drugs, 1997

Research

Serotonin and Norepinephrine Reuptake Inhibitors.

Handbook of experimental pharmacology, 2019

Research

Desvenlafaxine succinate for major depressive disorder.

Drugs of today (Barcelona, Spain : 1998), 2008

Guideline

Venlafaxine Dosing and Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The effect of renal disease on the disposition of venlafaxine.

Clinical pharmacology and therapeutics, 1994

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.